This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
Good news and bad news for asthma patients who use inhalers: You won't be expelling Earth-warming chlorofluorocarbons (CFC's) into the atmosphere with every puff, but you will pay six times as much for your green medical device.
Until now, inhalers have been powered by CFCs, which destroy the ozone layer. On Dec. 31, all albuterol inhalers will be propelled by hydrofluoroalkane (HFA), which is better for the environment, the Associated Press reports. But it will cost you: $30 to $60, compared with $5 to $10 now.
Albuterol is used on an emergency basis to open the airways of asthma patients suffering from severe wheezing. They take other, daily meds to control their asthma.
There are three green albuterol inhalers: GlaxoSmithKline's Ventolin HFA, Schering Plough's Proventil HFA and Teva Specialty Pharmaceuticals' ProAir HFA. Another, Sepracor's Xopenex HFA, contains a similar medication called levalbuterol.
Critics have questioned the need for the change, arguing that the steeper cost will hurt the disproportionately poor patients who need inhalers and that they are harder to use than the old kind. Users feel a softer puff, rather than the cold blast of the CFC-powered inhalers, and they need to cleaned (but not soaked) weekly to prevent clogging according to the AP.
"There's still significant confusion," pediatric allergist Harvey Leo of the University of Michigan's C.S. Mott Children's Hospital told the AP. "Patients will tell you, 'I don't feel the puff anymore."'
Image by iStockphoto/RMAX
